Show simple item record

AuthorIslam, Nazmul
AuthorLau, Colleen
AuthorLeeb, Alan
AuthorMills, Deborah
AuthorFuruya-Kanamori, Luis
Available date2022-03-20T07:18:16Z
Publication Date2022-01-01
Publication NameHuman Vaccines and Immunotherapeutics
Identifierhttp://dx.doi.org/10.1080/21645515.2021.2020573
CitationNazmul Islam, Colleen Lau, Alan Leeb, Deborah Mills & Luis Furuya-Kanamori (2022): Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia, Human Vaccines & Immunotherapeutics, DOI: 10.1080/21645515.2021.2020573
ISSN21645515
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85126091677&origin=inward
URIhttp://hdl.handle.net/10576/28326
AbstractLimited information is available about post-marketing safety of Japanese encephalitis (JE) vaccines. Using data from SmartVax, an active surveillance system for monitoring vaccine safety, adverse events following immunizations (AEFIs) were compared between the two JE vaccines available in Australia (a chimeric live attenuated vaccine [Imojev] and a Vero cell-derived inactivated vaccine [JEspect]). Data from 2756 patients (1855 Imojev and 901 JEspect) were included. Overall (7.0%), systemic (2.8%), and local (1.9%) AEFIs were uncommon. There were no significant differences in the odds of overall (OR = 1.27; 95%CI: 0.91–1.77), systemic (OR = 1.23; 95%CI: 0.74–2.06), or local (OR = 1.20; 95%CI: 0.65–2.22) AEFIs with Imojev compared to JEspect. There was an increase in odds of overall AEFI in patients aged <5 years (OR = 2.39; 95%CI: 1.10–5.19) compared to those aged >50 years. Both JE vaccines available in Australia are safe and well tolerated. Odds of AEFIs were age-dependent, young children should be carefully observed for AEFIs after vaccination.
Languageen
PublisherTaylor and Francis
SubjectImmunization
safety
SmartVax
tolerability
vaccination
TitleSafety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia
TypeArticle
ESSN2164-554X
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record